Potent estrogen receptor β agonists with inhibitory activity in vitro, fail to suppress xenografts of endocrine-resistant cyclin-dependent kinase 4/6 inhibitor-resistant breast cancer cells

ObjectiveSeventy percent of newly diagnosed breast cancers are estrogen receptor-α positive and HER2/neu negative. First-line treatments incorporate endocrine therapy and cyclin-dependent kinase 4/6 inhibitors. However, therapy resistance occurs in most patients. Hence, there is an urgent need for e...

Full description

Bibliographic Details

Published in:	Frontiers in Oncology
Main Authors:	Lynn M. Marcho, Christopher C. Coss, Menglin Xu, Jharna Datta, Jasmine M. Manouchehri, Mathew A. Cherian
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2025-03-01
Subjects:	ER+ breast cancer ERβ CDK4/6 inhibitor-resistant endocrine-resistant breast cancer
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2025.1441896/full